# InventisBio Announces Topline Results of a Phase III Study of Nomelcitinib (TYK2 Inhibitor), Demonstrating Promising Efficacy and Safety in Patients with Moderate to Severe Plaque Psoriasis.

- Source: PR Newswire M&A
- Published: 2026-11-02T11:00:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/inventisbio-announces-topline-results-of-a-phase-iii-study-of-nomelcitinib-tyk2-inhibitor-demonstrating-promising-efficacy-and-safety-in-patients-with-moderate-to-severe-plaque-psoriasis-302926256.html
- Canonical: https://groundlevelnews.com/story/inventisbio-announces-topline-results-of-a-phase-iii-study-of-nomelcit-0be1b4/

SHANGHAI, Nov. 2, 2026 /PRNewswire/ -- InventisBio Co., Ltd. today announced that its JH2 selective TYK2 inhibitor nomelcitinib (D-2570) has met both the primary endpoint and the key secondary endpoint in a registrational Phase III clinical trial for the treatment of moderate-to-severe...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._